ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response

• Published in: Molecular cancer research Vol. 16; no. 2; pp. 233 - 242
• Main Authors: Nikolos, Fotis, Thomas, Christoforos, Bado, Igor, Gustafsson, Jan-Åke
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research Inc 01.02.2018
• Subjects: Apoptosis; Breast cancer; Cancer; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - metabolism; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Chemotherapy; CHK1 protein; Damage; Deoxyribonucleic acid; Disease control; DNA; DNA Damage; DNA Repair - drug effects; Doxorubicin; Doxorubicin - pharmacology; Estrogen Receptor beta - genetics; Estrogen Receptor beta - metabolism; Estrogen receptors; Estrogens; Etoposide; Etoposide - pharmacology; G2 Phase Cell Cycle Checkpoints - drug effects; Gene expression; Gene Expression Regulation, Neoplastic - drug effects; Humans; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Non-small cell lung carcinoma; p53 Protein; Patients; Signaling; Transcription; Transfection; Tumor Suppressor Protein p53 - genetics; Tumors; Up-Regulation

The expression of wild-type estrogen receptor β (ESR2/ERβ1) correlates with clinical outcome in patients with non-small cell lung cancer (NSCLC). However, the molecular mechanism that accounts for this association is currently poorly understood. ERβ1 was previously linked to chemotherapy response in...